

From: [Robert Mcgaughy](#)
To: [Gary Kimmel](#)
Cc: [Larry Valcovic](#); [David Bayliss](#); [Ravi Subramaniam](#); [Bob Sonawane](#)
Subject: Progress on ETO
Date: 04/19/2002 10:55 AM

Gary,

In the week after our meeting, this is what I've done on ETO, relative to your

(b) (5)

▼ [Gary Kimmel](#)

**Gary
Kimmel**

04/18/2002
03:53 PM

To: Robert Mcgaughy/DC/USEPA/US@EPA, David Bayliss/DC/USEPA/US@EPA, Ravi Subramaniam/DC/USEPA/US@EPA, Hugh Tilson/RTP/USEPA/US@EPA, Larry Valcovic/DC/USEPA/US@EPA
cc: David Bussard/DC/USEPA/US@EPA, Bob Sonawane/DC/USEPA/US@EPA
Subject:

Below is an outline of the document that I developed from our discussion at last week's meeting. It includes the writing assignments. As agreed, everything except the Executive Summary should be **completed by 3 May 02.** In addition, there are issues/assignments that

we agree needed to be addressed. Please let me know if I've misstated anything.

ETHYLENE OXIDE

Derivation of a Cancer Inhalation Unit Risk Factor

Executive Summary **TEAM**

Introduction - Problem
Formulation **GARY**

Genetic Toxicity **LARRY**

Cancer Inhalation Unit Risk Factor

Human Cancer **DAVID**

Animal **BOB**

Derivation of the Risk Factor(s) - Human & Animal **BOB & RAVI**

OTHER ASSIGNMENTS:

Gary and Bob

- Do we need to incorporate pharmacokinetics into the document, and if so, how?

Bob and Ravi

- Estimate how the multiplicative model and the additive model differ, and discuss with Jim Cogliano re the cancer guidelines.
- Confirm with Dave Bayliss how he incorporates the Teta study/data.
- Are there competing standard curves that need to be fit to the Stayner data?

Bob

- Check with Aparna re whether we are being consistent in our approach with previous assessments.